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As the number of electronic biomedical textual resources increases, it becomes harder for physicians to
ﬁnd useful answers at the point of care. Information retrieval applications provide access to databases;
however, little research has been done on using automatic summarization to help navigate the docu-
ments returned by these systems. After presenting a semantic abstraction automatic summarization sys-
tem for MEDLINE citations, we concentrate on evaluating its ability to identify useful drug interventions
for 53 diseases. The evaluation methodology uses existing sources of evidence-based medicine as surro-
gates for a physician-annotated reference standard. Mean average precision (MAP) and a clinical useful-
ness score developed for this study were computed as performance metrics. The automatic
summarization system signiﬁcantly outperformed the baseline in both metrics. The MAP gain was 0.17
(p < 0.01) and the increase in the overall score of clinical usefulness was 0.39 (p < 0.05).
Published by Elsevier Inc.1. Introduction
The clinical research literature, particularly studies reporting
on randomized clinical trials, provides an important informa-
tion resource supporting effective patient care [1–4]. Compel-
ling evidence that is most relevant to a particular disease is
retrieved from online resources, especially MEDLINE, the
National Library of Medicine’s bibliographic database and the
primary repository of the scientiﬁc literature. However, as such
resources grow, it is increasingly challenging for clinicians to
rapidly ﬁnd useful answers to questions that arise during the
course of practice.
Search engines and biomedical information retrieval tech-
niques provide increased accuracy, ranking techniques, and
ways of presenting results [5–10] to the biomedical researcher
and clinician. However, little research has been published in
using automatic summarization to augment these techniques
and help manage the information contained in the large num-
bers of MEDLINE citations often returned by PubMed searches.
Automatic summarization seeks to provide the most important
information from a source in a condensed format. This ability
could support the practice of evidence-based medicine by allow-
ing, for example, users to compare and contrast several treat-
ments for a particular disease [11]. We are developing an
automatic summarization system in the semantic abstractionInc.
an).paradigm [12] that can potentially help clinicians ﬁnd the most
salient information relevant to some disease. The thrust of the
research reported here is to evaluate the summaries produced,
in an effort to determine how useful they are in helping clini-
cians provide quality patient care.
We conducted a formal, large-scale, topic-based evaluation of
our automatic summarization system, which found interven-
tions in the biomedical literature for several questions about
disorders. The questions and synthesized answers were semiau-
tomatically extracted from the June 2004 issue of Clinical
Evidence (CE) concise, a widely accepted resource for evi-
dence-based medicine compiled by the British Medical Journal
[13]. In addition, we enhanced this resource with disease–drug
information from the Physicians’ Desk Reference (PDR) [14],
which provides access to FDA-approved interventions for over
4000 drugs.
2. Background
2.1. Semantic abstraction summarization system
In research on automatic summarization a contrast is made
between processing a single text and several documents. To be
usefully applied in managing the results of PubMed searches,
multidocument applications are needed. Such systems have been
discussed in general and in speciﬁc domains. Teufel and Moens
[15] and Kupiec et al. [16] developed systems to summarize sci-
entiﬁc articles in general. Several systems in the computational
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domain areas, such as legal documents [20]. An example in
medicine is the PERSIVAL system [21]. Afantenos’ et al. [22] sur-
vey of summarization in the biomedical domain points out the
popularity of the extraction paradigm [23], in which summaries
consist of salient text identiﬁed in source documents. Other sys-
tems use semantic information to identify salient topics in scien-
tiﬁc articles [24], to generate summaries for news articles [25],
and to generate summaries of consumer health documents as
well as technical articles for physicians [26]. Earlier work investi-
gated the semantic abstraction paradigm [27], in which a sum-
mary is constructed from an abstract representation of the
semantic content of source documents.
We are developing a summarizer in the semantic abstraction
paradigm, and the system relies on semantic representation pro-
vided by SemRep [28,29], a natural language processing applica-
tion under development at the National Library of Medicine.
SemRep extracts semantic predications from the biomedical re-
search literature based on two principles: underspeciﬁed lin-
guistic analysis and domain knowledge from the Uniﬁed
Medical Language System (UMLS) [30]. For example, SemRep
interprets (1) as (2), where the arguments in this semantic pred-
ication, ‘‘Donepezil” and ‘‘Alzheimer’s Disease,” are Metathesau-
rus concepts, and the predicate, TREATS, is from the Semantic
Network.
(1) Donepezil for the management of Alzheimer’s Disease.
(2) Donepezil TREATS Alzheimer’s Disease
The predications produced by SemRep comprise executable
knowledge representing semantic information in the documents
processed and can be reduced by the summarization process to
provide an overview of those documents from four points of view
(treatment of disease, diagnosis of disease, pharmacogenomics,
and substance interactions). In this paper, we used the treatment
of disease point of view.
Summarization relies on a user-speciﬁed topic and a transfor-
mation phase based on four principles which ensure that the sum-
mary provides useful information on the topic [12]. The principles
are informally deﬁned as:Fig. 1. A schematic view of our sem(3)anticRelevance: Include predications on the topic of the summary
Connectivity: Also include ‘‘useful” additional predications
Novelty: Do not include predications that the user already
knows
Saliency: Only include the most frequently occurring
predicationsIf ‘‘pneumonia” is selected as the topic of the summary, Relevance
processing keeps predications with ‘‘Pneumonia” as an argument,
such as ‘‘Ampicillin TREATS Pneumonia” but excludes all others
(for example, ‘‘Doxorubicin TREATS Hodgkin’s Disease”). Connec-
tivity includes predications that share an argument with a predi-
cation kept by Relevance (such as ‘‘Ampicillin CAUSES Rash”).
Novelty uses the hierarchical structure of the Metathesaurus to
eliminate predications with generic (and hence uninformative)
arguments such as ‘‘Pharmaceutical Preparation TREATS Pneumo-
nia.” Finally, Saliency eliminates predications with low frequency
of occurrence [31].
A high-level view of the summarization process evaluated in
this study is illustrated in Fig. 1. The results of a PubMed search
are ﬁrst interpreted by SemRep. The summarizer then takes these
predications as input along with a user-speciﬁed topic (such as a
disease) and applies the transformation principles to produce a re-
duced set of predications (or conceptual condensate), which gives
an overview of the content of the retrieved citations. Finally, the
condensate is represented as a graph, which is both informative,
in the sense that it provides an overview of the content of the
source citations, and indicative, in that predications are linked to
the source text that generated them.
An example of output from this system is given in Fig. 2, where
the graph represents semantic predications produced by summa-
rizing 300 MEDLINE citations returned by a PubMed search on
panic disorder. Nodes in the graph represent concepts, and arcs
show relations between them. (Only TREATS relations are dis-
played in Fig. 2.) Drug therapies, such as selective serotonin reup-
take inhibitors, tricyclic antidepressants (imipramine), and
benzodiazepines appear in the graph and are included as effective
interventions in CE. Perhaps more interestingly, cognitive therapy
and psychotherapy, of particular interest for anxiety disorders,
are prevalent in the summary but are not included in the Juneabstraction summarizer.
Fig. 2. Partial display of the results of summarizing 300 MEDLINE citations returned by a PubMed search on panic disorder (only interventions or TREATS predications are
shown).
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ventions will be considered for future releases.) In Fig. 2, the arc
linking ‘‘Cognitive Therapy” to ‘‘Panic Disorder” has been selected
and the information in the box on the right indicates that this
TREATS relation occurs 17 times (frequency of occurrence) in 11 of
the citations returned by the search (typicality). One of these cita-
tions is shown in the box at the bottom; it reports on a multicenter
trial of different delivery methods of cognitive-behavioral therapy
for the treatment of panic disorder.
2.2. Related research on evaluating multidocument summarization
Evaluation of multidocument summarization is an evolving re-
search ﬁeld. In most studies [32–34], reference standard summa-
ries are produced by several experts, and measures of intra- and
inter-rater agreement are provided. The summarizers are con-
trasted quantitatively with these reference standards and several
performance measures are computed. This methodology is expen-
sive and time consuming. In addition, generating an ideal summary
is subjective with respect to the experts who produce them. Be-
cause of this, research is being pursued to produce reference stan-
dards automatically [35].
Other evaluation studies are user centered. Typically this meth-
od has been deployed for single document summarization [36] and
seeks to assess a summary based on how well a user can exploit it
to perform a given task. Evaluation studies of multidocument sum-
marization in the biomedical [37] and news (for example [38]) do-
mains attempt to measure the impact that multidocument
summarization has on a user’s ability to ﬁnd answers quickly whilesatisfying information needs. After reading summaries, users are
asked to answer questions related to ﬁnding required information,
exploiting that information, and user satisfaction.
More recently Amigo et al. [39] proposed an ‘‘information syn-
thesis” task, deﬁned as ‘‘given a speciﬁc information need, the mul-
tidocument summary should extract, organize, and synthesize an
answer that satisﬁes that need.” Based on this proposal, the annual
Document Understanding Conference (DUC) [40] was reengineered
to address a more focused, topic-oriented approach to evaluating
automatic summarization systems. The topic invokes real-world
questions and human assembly of answers so they can be com-
pared against the results of the summarizers.
In this study, we followed the information synthesis approach
of Amigo et al. in an effort to determine how interventions that ap-
pear in our summaries as subject arguments of TREATS predica-
tions compare with interventions in a reference standard
generated semiautomatically from two widely accepted resources
for evidence-based medicine, CE and PDR. Therefore, we took
advantage of these resources as surrogates for answers assembled
by hand, and very little human involvement was necessary in the
creation of the reference standard. These resources will be brieﬂy
introduced in the next section, and compilation of the reference
standard will be discussed in detail in Section 3.
2.3. Resources for evidence-based medicine
The June 2004 issue of CE was used to create the reference stan-
dard for evaluation of the generated summaries. CE is one of the
so-called secondary sources of evidence-based information for
Table 1
Topics included in this study. Diseases and classes are deﬁned in Clinical Evidence
concise.
Disease class Topic
Blood and lymph
disorders
Early stage aggressive non-Hodgkin’s lymphoma
Cardiovascular
disorders
Acute myocardial infarction, acute ischemic stroke, atrial
ﬁbrillation, heart failure, unstable angina
Child health Acute otitis media
Digestive system
disorders
Gastroesophageal reﬂux disease, irritable bowel syndrome
Ear, nose, and throat
disorders
Acute sinusitis, otitis externa, seasonal allergic rhinitis
Endocrine disorders Hypothyroidism, obesity
Eye disorders Bacterial conjunctivitis, glaucoma
HIV and AIDS Pneumocystis carinii pneumonia
Infectious diseases Chickenpox, congenital toxoplasmosis, acute diarrhea,
malaria, bacterial meningitis
Men’s health Chronic prostatitis, erectile dysfunction
Mental health Dementia, depressive disorders, generalized anxiety
disorder, mania, panic disorder, post-traumatic stress
disorder, schizophrenia
Musculoskeletal
disorders
Acute low back pain, leg cramps, osteoarthritis,
osteoporosis, rheumatoid arthritis
Neurological
disorders
Epilepsy, migraine, multiple sclerosis, Parkinson’s Disease,
trigeminal neuralgia
Oral health Oropharyngeal candidiasis
Respiratory disorders
(acute)
Acute asthma, acute bronchitis, community acquired
pneumonia
Respiratory disorders
(chronic)
Chronic asthma, chronic obstructive pulmonary disease
Sexual health Chlamydia infection, genital warts, gonorrhea
Skin disorders Atopic eczema, chronic psoriasis, scabies, tinea pedis
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ries of the best available clinical research. CE summaries are pre-
sented as answers to clinical questions. Each summary includes a
list of interventions, key points and synopses of the reviewed clin-
ical studies, references, and supplements for a particular disorder.
The usefulness of this resource comes from the ordered categorical
output of the list of interventions. For example, for the question
‘‘What are the treatments for osteoarthritis?” CE has an ordered list
of interventions such as oral analgesics, oral nonsteroidal antiin-
ﬂammatory agents, exercise, etc. This structure of CE facilitates
semiautomatic extraction of interventions needed to compile a ref-
erence standard. The ordered categories deﬁned for CE interven-
tions are:
Beneﬁcial (Interventions for which effectiveness has been
demonstrated by clear evidence from randomized clinical trials
and for which expectation of harm is small compared with the
beneﬁts).
Likely to be beneﬁcial (Interventions for which effectiveness is
less well established than for those listed under ‘‘beneﬁcial”).
Trade-off between beneﬁts and harms (Interventions for which
clinicians and patients should weigh up the beneﬁcial and harmful
effects according to individual circumstances and priorities).
Unknown effectiveness (Interventions for which there are cur-
rently insufﬁcient data or data of inadequate quality).
Unlikely to be beneﬁcial (Interventions for which lack of effec-
tiveness is less well established than for those listed under ‘‘likely
to be ineffective or harmful”).
Likely to be ineffective or harmful (Interventions for which inef-
fectiveness or harmfulness has been demonstrated by clear
evidence).
In addition to CE, we used the 2004 version of the PDR, which
lists drugs approved by the FDA for the treatment of disease. It
does not provide ordered categories, but it compensates for the
intentional sparseness of CE in a manner that will be explained
in the next sections.
3. Methods
For our topic-based approach to automatic summarization
evaluation, we adapted methods developed by the National Insti-
tute of Standards and Technology for the DUC and Text Retrieval
Conference (TREC). These evaluations rely on: (1) topics (descrip-
tions of complex information needs, recently expressed as ques-
tions), (2) documents for summarization, (3) reference
standards, and (4) evaluation metrics. We used topics and sum-
maries compiled by medical experts and published in CE. In our
collection, each topic is a question about pharmacotherapy for a
given disorder. The corresponding summary answers this ques-
tion by providing a ranked list of therapeutic interventions. We
evaluated the system using widely accepted measures of perfor-
mance developed in TREC and an evaluation metric developed
for this study. The latter metric strives to capture the usefulness
of the summaries for evidence-based medicine. The results from
our summarization system were compared to a baseline in which
answers were based solely on frequently occurring drugs in re-
trieved documents. Finally, we conducted a manual evaluation
of four randomly selected topics.
3.1. Topics and reference standard
All questions from the CE 2004 issue pertaining to pharmaco-
logical treatment of diseases were included in this study (questions
about therapeutic procedures such as surgery were excluded). Of
the 192 CE topics, 54 questions matched the inclusion criterion.
The corresponding topics (disorders) are listed in Table 1 along
with the disease classes to which they belong (determined byCE). The 54 topics are expressed as follows (with minor variations)
in CE: What are the effective treatments for X? (X represents disor-
ders such as chronic obstructive pulmonary disease.)
The reference standard intervention lists for the 54 topics were
formed as follows: The core of the reference standard consists of
the interventions extracted manually from the CE 2004 issue. CE
provides information for an international audience; therefore, only
the generic or the most common names of drugs (rather than
brand names) are used in the summaries. Further, CE does not in-
clude all FDA-approved drugs. To compensate for this sparseness,
drugs for each topic were manually extracted from PDR and added
to the reference standard as a separate group. Including PDR drugs
also addressed the fact that CE does not include brand names of
drugs. Each CE drug name in the reference standard was annotated
with its category (such as ‘‘beneﬁcial,” ‘‘trade-off,” or ‘‘likely harm-
ful”), while the PDR drugs were labeled ‘‘pdr.” For a given topic, if
both sources (CE and PDR) contained a drug name, only its CE cat-
egory was used.
After compiling lists of drugs for each topic, the reference stan-
dard was normalized by mapping drug names to UMLS Metathe-
saurus concepts using MetaMap [41]. To provide for subsequent
automatic evaluation (in which drugs found by the summarization
system and the baseline method were matched against the refer-
ence standard on a conceptual level), drug names were represented
in the reference standard using UMLS unique concept identiﬁers
(CUI). The majority of the UMLS CUIs for the reference standard
were determined automatically; however, CUIs for a few un-
matched drugs were assigned by the second author (DDF), who
was not involved in the development of the summarization sys-
tem. Manual assignment of CUIs was necessary to accommodate
spelling variation and synonymy not represented in the Metathe-
saurus and to disambiguate multiple matches. The reference stan-
dard was created independently and in advance of the summaries
generated by the summarization system and the baseline method.
Table 2 presents the reference standard entry for the topic panic
disorder.
Table 2
Reference standard entry for panic disorder.
CE/PDR intervention
name
UMLS concept Treatment
category
Selective serotonin
reuptake inhibitors
C0162758: Serotonin Uptake Inhibitors Beneﬁcial
Tricyclic antidepressants C0003290: Antidepressive Agents,
Tricyclic
Beneﬁcial
Imipramine C0020934: Imipramine Beneﬁcial
Benzodiazepines C0005064: Benzodiazepines Trade-off
Buspirone C0006462: buspirone Unknown
Monoamine oxidase
inhibitors
C0026457: Monoamine Oxidase
Inhibitors
Unknown
Paroxetine hydrochloride C0070122: Paroxetine C0771019:
Paroxetine Hydrochloride
pdr
Sertraline hydrochloride C0074393: Sertraline C0600526:
Sertraline Hydrochloride
pdr
Clonazepam C0009011: Clonazepam pdr
Alprazolam C0002333: Alprazolam pdr
Fluoxetine hydrochloride C0733380: Fluoxetine Hydrochloride
C0016365: Fluoxetine
pdr
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MEDLINE citations for the summarization system and the base-
line were retrieved automatically by submitting a query template
(Fig. 3) to PubMed using EUtilities [42]. The template emulates
search strategies employed by medical librarians seeking high
quality information focused on a particular disease: (1) To focus
on the disease in question, the default PubMed query expansion
was turned off using the [mh:noexp] command. For example, this
strategy prevents broadening the search for ‘‘epilepsy” to a search
for 25 disorders, including ‘‘Seizures,” ‘‘Febrile Seizures,” and ‘‘Lan-
dau–Kleffner Syndrome.” (2) To focus on high quality evidence, the
search was limited to the results of clinical trials. Although meta-
analyses and systematic reviews are considered high quality sec-
ondary sources of evidence, we followed the strategies developed
by the authors of these studies and focused on reliable primary
sources of evidence. Further, to be as close as possible to knowl-
edge available at the time of the creation of CE, we restricted the
date of the search to articles published prior to the publication of
the CE article for a given disease. To ﬁll the term variable in this
template, each topic in Table 1 was mapped to MeSH using Meta-
Map. We found that a few of the resulting MeSH concepts did not
adequately convey the meaning of the topic, and we therefore
modiﬁed the names of these topics and remapped them to MeSH.
For example, initially ‘‘oropharyngeal candidiasis” was mapped to
MeSH ‘‘Candidiasis,” while the manually modiﬁed ‘‘oral candidia-
sis” was mapped to the more speciﬁc ‘‘Candidiasis, Oral.” The mod-
iﬁcations are as follows:
oropharyngeal candidiasis ? oral candidiasis
chronic bacterial prostatitis ? chronic prostatitis
chronic plaque psoriasis ? chronic psoriasis
early stage aggressive non-Hodgkin’s lymphoma ? early stage
non-Hodgkin’s lymphomaFig. 3. PubMed search template where $term, $rest_of_the_words, $year, and
$month denote respectively a MeSH term, words not mapped to MeSH, a year and a
month in which a CE summary was created.The PubMed query based on the template in Fig. 3 is general
and was used for the 54 topics of our evaluation. The number of
citations returned varied depending on the topic. For example,
there were no results of clinical trials published speciﬁcally on
‘‘Irritable Bowel Syndrome” before 2004. Since, the search returned
no citations, this topic was ignored for subsequent processing, and
the study was conducted with 53 topics. There were few trials pub-
lished on four other topics (early stage aggressive non-Hodgkin’s
lymphoma, congenital toxoplasmosis, generalized anxiety disor-
der, and leg cramps), and search results were consequently low.
Although results for these topics were included in the study, sum-
marization system results were affected.
3.3. Baseline generation
To evaluate the usefulness of the summarization system for evi-
dence-based practice, we compared it to a baseline in which sum-
maries were generated using simple frequency of occurrence of
drug names in retrieval results. The baseline was created using
MetaMap. Concepts having a semantic type in the UMLS semantic
group Chemicals & Drugs were identiﬁed in the PubMed search re-
sults for each of the 53 topics in our study (excluding ‘‘Irritable Bo-
wel Syndrome”). The ﬁve most frequently occurring drugs in the
set of documents for each disorder were then extracted as the list
of drugs considered to be pharmacotherapies for that disorder. The
ﬁve most frequently occurring drugs were selected, because, on
average, there are ﬁve beneﬁcial and likely beneﬁcial drugs listed
in CE for each disorder. The baseline method, emphasizing fre-
quency of occurrence, may approximate a busy clinician investi-
gating therapeutic alternatives when confronted with a particular
disease.
3.4. Summaries generated by the summarization system
For each of the 53 topics in the study, the retrieved document
set was processed using SemRep, and the predications returned
were summarized with the relevant topic speciﬁed as the main
topic of the summary. From the summarized conceptual conden-
sate we extracted predications of the form <Intervention> TREATS
<Disorder> where <Disorder> is the UMLS Metathesaurus concept
corresponding to the topic, and <Intervention> is any Metathesau-
rus concept having a semantic type in the semantic group Chemi-
cals & Drugs. Final ranked lists of drug therapies for each topic
were created by extracting <Intervention> concepts and sorting
them by frequency of occurrence.
For four topics (early stage aggressive non-Hodgkin’s lym-
phoma, congenital toxoplasmosis, generalized anxiety disorder,
and leg cramps) the summarization system produced no results
because the number of citations retrieved for these topics was
small (as noted above), leaving the output for summarization
either empty or with no TREATS relations. For example, PubMed
retrieved two citations for congenital toxoplasmosis; there were
no TREATS predications in the summarization output for these
citations.
3.5. Evaluation
Determining whether a drug name found by the summarization
system belongs to the reference standard as a treatment for the rel-
evant topic is fairly complex because of the nature of CE, on which
the reference standard was based. Different, but synonymous, drug
names occurring in the reference standard and retrieved by the
summarization system are accommodated by synonymous con-
cepts in the UMLS Metathesaurus. However, in many cases the ref-
erence standard names a class of drugs as beneﬁcial for a given
topic, for example, thrombolytic agents for acute myocardial
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marization system should be counted as a true positive. The hier-
archical matching algorithm described in Section 3.5.1 performs
this task automatically. Hierarchical matching is followed by com-
putation of mean average precision (Section 3.5.2). Although this
metric is useful in predicting future performance of a system with
respect to ﬁnding drugs mentioned in the reference standard, it
does not rate beneﬁcial drugs higher than harmful ones. We there-
fore developed a metric, the clinical usefulness score, which takes
into consideration the quality of the intervention found (Section
3.5.3). We computed mean average precision and the clinical use-
fulness score for each disease topic and then averaged the scores
within each disease class. An overall schematic view of our evalu-
ation is depicted in Fig. 4.
3.5.1. Hierarchical matching
As the basis for hierarchical matching, we used the UMLS
Knowledge Source Server [43] to retrieve Metathesaurus hierar-
chical contexts for drugs returned by the summarization system
and the baseline method. For example, ‘‘Thrombolytic Agents”
was computed as an ancestor of ‘‘Tissue Plasminogen Activator.”
Drug names returned by the summarization system or the base-
line method were allowed to match their ancestors, thus reconcil-
ing a drug name returned by the summarization system with its
class in the reference standard. However, a class from the sum-
marization system (acetylcholinesterase inhibitors, for example)
compared to a member in the reference standard (donepezil)
was marked as a false positive.
3.5.2. Mean average precision
Mean average precision (MAP) is a measure sensitive to the
ranking of drugs by a system and summarizes both recall and pre-
cision [44]. MAP for the 53 topics was computed as the mean of the
individual average precision scores for each topic. Average preci-
sion of each topic is the mean of the precision scores computed
after each reference standard drug is found in the ranked list of
drugs generated by the summarization system and the baseline
method. Based on the 53 disease topics, we calculated MAP for
the 18 disease classes presented in Table 1 by computing the aver-
age MAP scores for the topics in each class.Fig. 4. An overall view of the3.5.3. Clinical usefulness score
To evaluate the usefulness of the summarization system and the
baseline method in a clinical setting, a categorical performance
metric was developed speciﬁcally for this study. In calculating this
score, interventions extracted by a system are assigned to one of
four high-level categories depending on how they match the inter-
ventions in the reference standard. The goal is to give credit to the
system for ﬁnding beneﬁcial interventions and, similarly, penalize
it for ﬁnding harmful interventions. The high-level categories and
the corresponding reference standard categories are as follows:
BEST: beneﬁcial, likely to be beneﬁcial
OK: trade-off between beneﬁts and harms, pdr
BAD: likely to be ineffective or harmful
OTHER: unknown effectiveness, unlikely to be beneﬁcial
We compared summarization and baseline results with the ref-
erence standard using hierarchical matching and assigned each
intervention extracted to one of these high-level categories. We
then computed scores for each of these four categories for each dis-
ease class of Table 1. The score is normalized by dividing the num-
ber of interventions in the category by the total number of
interventions extracted by the summarization process.
An overall score of clinical usefulness is computed as follows:
Overall score ¼ wb  BEST scoreþwokOK scorewoOTHER score
wp  BAD score
Where:
D: total # of drugs from system (summarization or baseline)
BEST score = (# of beneﬁcial + # of likely beneﬁcial)/D
OK score = (# of trade-off + # of pdr)/D
BAD score = (# of likely harmful)/D
OTHER score = 1  (BEST score + OK score + BAD score)
The BEST category is given more weight (wb coefﬁcient) because
it is more important to ﬁnd a highly beneﬁcial treatment than to
ﬁnd an intervention of questionable effectiveness (OK category).
Similarly, the summarization system and the baseline methodevaluation methodology.
Table 4
Mean average precision scores for disease classes for baseline (BASE) and the
summarization system (SUM). In the ﬁrst column, N is the number of topics in a
disease class. The last column is the gain in MAP.
Disease class Topic (N) BASE SUM MAP gain
Oral health 1 0.10 1.00 0.90
Digestive system disorders 1 0.06 0.71 0.65
Respiratory disorders (chronic) 2 0.15 0.78 0.63
Musculoskeletal disorders 5 0.36 0.78 0.43
Respiratory disorders (acute) 3 0.08 0.47 0.38
Endocrine disorders 2 0.50 0.83 0.33
Mental health 7 0.49 0.69 0.20
Cardiovascular disorders 5 0.50 0.60 0.11
Ear, nose, and throat disorders 3 0.21 0.31 0.10
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a harmful intervention than for ﬁnding a treatment of unknown
effectiveness (OTHER category). The overall score is a number that
takes into consideration the degree of usefulness of an interven-
tion. This score is potentially meaningful in evaluating relative per-
formance of several systems on a given test set. As the weights wb
and wp are constant, their absolute values represent an evaluator’s
belief in the importance of a given category. In this study both
coefﬁcients were (intuitively) set to 3, with the consequence that
a drug with the BEST score is considered to be three times more
useful than one with an OK score, which is in turn three times
more useful than a drug with a BAD score.
We tested for statistically signiﬁcant differences between the
performance measures (mean average precision and clinical use-
fulness score) for the summarization system and the baseline for
all disease classes using a two-tailed Wilcoxon signed rank test
with 5% signiﬁcance level. In addition, we used Kendall’s tau [45]
to determine whether mean average precision and the clinical use-
fulness score were correlated with each other.
3.5.4. Manual evaluation
Automatic comparison of system results to the reference stan-
dard is less resource intensive than relying on humans, but is not
as accurate. In an effort to provide additional insight into the effec-
tiveness of the summarization system for providing clinically rele-
vant information, we conducted a manual evaluation for a random
sample of four topics: acute myocardial infarction, gastroesopha-
geal reﬂux disease, community acquired pneumonia, and panic
disorder. Intervention concepts returned by the summarization
system were marked as being correct only if they matched a drug
in the reference standard categories ‘‘beneﬁcial” or ‘‘likely to be
beneﬁcial.” Recall and precision were calculated by hand.
4. Results
Appendix A shows all the interventions found by the summari-
zation system for each of the topics in the study. As mentioned be-
fore, irritable bowel syndrome was excluded, leaving the digestive
system class with one topic, for a total of 53 topics in all classes.
Also, as explained before, the summarization system produced no
results for four topics (early stage aggressive non-Hodgkin lym-
phoma, congenital toxoplasmosis, generalized anxiety disorder,
and leg cramps). For the 53 topics, the number of citations repre-
sented in the ﬁnal summary varied from 2 to 500 with an average
of 240. The number of interventions for the topics varied from 0 to
26 with an average of 9. In the last column of Appendix A, the
interventions retrieved for each topic are displayed in descending
order of frequency of occurrence and typicality. All the interven-
tions in Appendix A are UMLS Metathesaurus concepts.
Table 3 compares results from the summarization system to the
baseline (determined exclusively by frequency of occurrence) and
lists ﬁve interventions from each method that were found to treat
the dementia topic (mental health class). Underlined are interven-
tions considered beneﬁcial (‘‘Donezepil”) and likely to be beneﬁcial
(‘‘Gingko biloba extract”) according to the reference standard and
found by the summarization system, but not by the baseline meth-Table 3
Interventions for the topic dementia. Those considered ‘‘beneﬁcial” or ‘‘likely to be
beneﬁcial” in the reference standard are in italics.
Summarization system Baseline
Donepezil Pharmaceutical Preparations
Ginkgo biloba extract Antipsychotic agents
Antipsychotic Agents Risperidone
Risperidone Haloperidol
Olanzapine Olanzapineod. The uninformative concept ‘‘Pharmaceutical Preparations” is
eliminated by the summarization system but occurs in the base-
line. The other interventions are ‘‘Antipsychotic agents” such as
‘‘Risperidone,” ‘‘Haloperidol,” and ‘‘Olanzapine.” These are used to
control behavioral and psychological symptoms of dementia, but
do not improve the disease and are listed as ‘‘trade-off between
beneﬁts and harms” by the reference standard.
As noted, in order to assess effectiveness of the summarization
system we calculated both MAP and a clinical usefulness score. Ap-
proaches to evaluating the system should reﬂect the intended task.
For example, if the goal is to display a ranked list of treatments
classiﬁed from useful to harmful, MAP better predicts future
performance. However, if the task is to display only the top-ranked
effective treatments, the clinical usefulness score is a better evalu-
ation metric.
Table 4 shows mean average precision for the baseline method
and summarization system on identifying reference standard inter-
ventions for the disease classes noted in Table 1, sorted in descend-
ing order of MAP gain between results from the summarization
system and the baselinemethod (last column). MAP gain computed
over all disease classes is statistically signiﬁcant (p < 0.01).
Table 5 shows the results for the overall score of clinical useful-
ness for the baseline method and the summarization system. The
negative values in the third and fourth columns indicate that the
summarization system either completely failed to ﬁnd the best
available treatments, or the proportion of the beneﬁcial drugs was
insigniﬁcant compared to the number of harmful drugs found by
the system. The last columnof the table shows the gain in the overall
clinical usefulness score with respect to the baseline in descending
order. The overall difference in usefulness score between results
for the baseline method and the summarization system is statisti-
cally signiﬁcant (p < 0.05). Although, both performance measures
showedsigniﬁcant improvementover thebaseline theyonlymoder-
ately correlate with each other (Kendall’s tau = 0.34), which means
they are measuring performance in different ways.
Tables 4 and 5 demonstrate that according to both scores the
summarization system performed better than the baseline method
for such disease classes as oral health, respiratory disorders, mus-
culoskeletal disorders, mental health, and digestive system
disorders. On the other hand, the summarization system produced
degraded results with respect to the baseline for the HIV and AIDS
disease class. Results for other disease classes vary depending onSexual health 3 0.42 0.52 0.09
Men’s health 2 0.38 0.46 0.07
Skin disorders 4 0.22 0.23 0.01
Neurological disorders 5 0.41 0.42 0.01
Infectious diseases 5 0.28 0.28 0
Blood and lymph disorders 1 0.00 0.00 0.00
Child health 1 0.03 0.00 0.03
Eye disorders 2 0.08 0.00 0.08
HIV and AIDS 1 0.84 0.51 0.33
All 53 0.33 0.50 0.17+
+ Statistical signiﬁcance (p < 0.01).
Table 5
Overall score of clinical usefulness for the baseline (BASE) and summarization system
(SUM). The last column is the gain in the overall clinical usefulness score.
Disease class Topic (N) BASE SUM Overall-gain
Oral health 1 0.20 2.50 2.70
Respiratory disorders (acute) 3 0.33 1.00 1.33
Respiratory disorders (chronic) 2 0.00 0.86 0.86
Digestive system disorders 1 0.60 0.23 0.83
Mental health 7 0.49 1.11 0.62
Musculoskeletal disorders 5 0.36 0.89 0.53
Infectious diseases 5 0.36 0.04 0.40
Skin disorders 2 0.10 0.16 0.26
Ear, nose, and throat disorders 4 0.73 0.92 0.19
Eye disorders 3 0.40 0.23 0.17
Men’s health 2 0.00 0.09 0.09
Child health 5 1.00 1.00 0.00
Neurological disorders 1 0.36 0.36 0.00
Blood and lymph disorders 1 1.00 1.00 0.00
Sexual health 3 0.87 0.69 0.18
Cardiovascular disorders 5 0.84 0.64 0.20
Endocrine disorders 2 0.00 0.33 0.33
HIV and AIDS 1 2.20 1.67 0.53
All 53 0.25 0.64 0.39+
+ Statistical signiﬁcance (p < 0.05).
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possible reasons for these results. We also discuss drugs found
by the summarization system that occur in the literature as valid
interventions for speciﬁed disorders, but which are not included
in the reference standard.
The results of the manual evaluation performed are presented
in Table 6. Recall is strong, but precision less so.
5. Discussion
Overall, our results support the hypothesis that automatic sum-
marization can make a positive contribution to effective clinical
care by managing the information contained in MEDLINE citations
relevant to speciﬁc topics. The overall statistically signiﬁcant MAP
gain with respect to the baseline was 0.17. The overall improve-
ment in the clinical usefulness score was 0.39, which reﬂects the
summarization system’s ability to ﬁnd interventions that have
been proven beneﬁcial or are likely to be beneﬁcial according to
the reference standard. These gains were achieved despite a rela-
tively strong baseline, generated by using MetaMap conceptual
normalization to identify drugs in citations retrieved with a
focused search on speciﬁc topics.
The improvement in several disease classes (for example mus-
culoskeletal disorders, mental health, and respiratory disorders)
can be attributed to predication-based summarization. This meth-
od takes advantage of predications of the form ‘‘<Intervention>
TREATS <Disorder>” produced by SemRep in order to focus drug
therapies on the topic (Relevance processing). For example, if the
question was for treatment of acute asthma, the summary will
not retrieve interventions for chronic asthma. Further, in the Nov-
elty phase, the summarization system prunes predications with
arguments that are uninformative. Therefore, in general, a nonspe-
ciﬁc concept such as ‘‘Pharmaceutical Preparations” (which does
not appear in the reference standard) is always eliminated.Table 6
Manual comparison between summarization and the reference standard.
Topic Recall (%) Precision (%)
Acute myocardial infarction 95 94
Gastroesophageal reﬂux disease 100 54
Community-acquired pneumonia 100 78
Panic disorder 100 57
Overall 98 73Although, the summarization system performed better than the
baselinemethod formostdisease classes, for others, resultswereun-
changed or degraded. In some cases, degraded results were ulti-
mately due to UMLS Metathesaurus coverage. For example, in the
HIV and AIDS class (which has one disease, pneumocystis carinii
pneumonia) bothMAP and the clinical usefulness score were better
for the baseline than for results from the summarization system.
Both the summarization system and baseline processing retrieved
four drugs that appear in the reference standard as beneﬁcial in
the treatment of pneumocystis carinii pneumonia in HIV patients:
trimethoprim–sulfamethoxazole combination, pentamidine, corti-
costeroids, and dapsone. Additional interventions found by both
the baseline method and the summarization system are not in the
reference standard. Zidovudine, a drug used against the HIV virus,
but not for the treatment of pneumocystis carinii pneumonia, ap-
pears in the baseline as a false positive. ‘‘Prophylactic treatment”
andhydroxynaphthoquinone566C80were returnedby the summa-
rization system, neither of which is in the reference standard. Be-
cause the summarization system found one more false positive
than the baselinemethod, it received a lower performancemeasure
than the baseline. In fact, hydroxynaphthoquinone 566C80 is a syn-
onym for atovaquone, which appears in the reference standard as
beingbeneﬁcial forpneumocystis carinii pneumonia.Unfortunately,
this equivalence is not represented in theMetathesaurus. Errors due
to unnamed synonymy in theMetathesaurus degraded summariza-
tion system results in several other disease classes as well.
Mapping to the Metathesaurus during the process of generating
semantic predications produced several errors. For example, the
noun dose wrongly matched the Metathesaurus concept ‘‘DOS,”
which is a synonym for docusate, a stool softener. Similarly infelic-
itous mappings produced other false positives, such as ‘‘The sci-
ence and art of healing” and ‘‘Stimulation–action.”
The etiology of another class of errors involves curation policy
in creating a secondary evidence-based resource such as CE. Inter-
ventions are included only when there is sufﬁcient evidence to
support a determination of their effectiveness. For example,
although baclofen is discussed in the research literature as a prom-
ising drug for gastroesophageal reﬂux disease, it does not appear in
the version of CE we used for the reference standard in this study
(nor does it appear in PDR for this disease). Since our summariza-
tion system does not have access to CE curation policy, it retrieved
baclofen as a treatment for gastroesophageal reﬂux disease based
on a predication accurately extracted from the following text in
MEDLINE: ‘‘Effect of acute and chronic administration of the GABA
B agonist baclofen. . ..in control subjects and in patients with gas-
troesophageal reﬂux disease” (PMID 12631652).
In analyzing the results of the manual evaluation, false positives
can be classiﬁed into four types. In descending order of frequency
they are: intervention concepts that are categorized ‘‘trade-off or
unknown effectiveness” (43%) or do not appear in the reference
standard (29%), intervention concepts that are too general (21%),
and infelicitous mappings to the UMLS Metathesaurus (7%). The
majority of the errors were of the ﬁrst two types and are related
to CE curation policy. For example, ‘‘Antacids” (for gastroesopha-
geal reﬂux disease) and ‘‘Alprazolam” (panic disorder) were re-
trieved by the summarization system but are classiﬁed in the
‘‘trade-off” or ‘‘unknown effectiveness” category. The second error
type included interventions that do not appear in the reference
standard, such as ‘‘Baclofen” (gastroesophageal reﬂux disease).
These interventions are discussed in MEDLINE and may be in-
cluded in later versions of CE. Errors of the other two types reﬂect
shortcomings of the summarization system; however, they are less
frequent than those in the ﬁrst two types. ‘‘Antibiotics” (for com-
munity acquired pneumonia) is an example of a concept that is
too general, and ‘‘Administration (procedure)” (acute myocardial
infarction) is due to an incorrect mapping to the Metathesaurus.
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considered pharmacologic treatments, and did not address topics
for which the primary intervention is a therapeutic procedure. In
addition, CE does not include information on diagnosis or progno-
sis, and so the evaluation does not provide insight on system per-
formance in these areas. Other curated resources (such as
UpToDate) could be explored as a basis for extending the method-
ology discussed here beyond treatment. A further limitation is due
not so much to the evaluation methodology as to the natural lan-
guage processing system assessed, which does not have access to
information about the quality of the evidence supporting the rele-
vant intervention [46]. This kind of information supports CE inter-
vention categorization, and taking it into account would likely
decrease the number of false positives returned by the system
(especially in the ‘‘trade-off” and ‘‘unknown effectiveness” catego-
ries). Research is being pursued on automatic determination of
quality of evidence [47,48]; such processing could be incorporated
into the summarization system.
Although this paper concentrated on evaluating automatic sum-
marization with a view toward assisting clinicians in navigating
MEDLINE, it is also attractive to consider the system described as
a possible tool for developing secondary sources of information
such as CE. The construction (and updating) of these resources is
labor-intensive and expensive. The system presented above could
potentially support curators in their work.
6. Conclusion
Physicians have access to an ever increasing number of online
resources to support high quality patient care. Current research
in biomedical information management technology provides sev-
eral retrieval techniques to help ﬁnd the most useful documents
relevant to questions that arise during clinical practice. However,
few studies have investigated automatic summarization as a po-
tential tool to help navigate the retrieved documents. We describea system based on semantic abstraction that summarizes MEDLINE
citations discussing treatment for speciﬁed disorders. A graphical
display gives an informative overview of the processed informa-
tion, while links to the underlying documents allow access to de-
tails. This paper then concentrates on a formal evaluation of the
accuracy of this automatic summarization system in identifying
treatments for disorders.
We used a topic-oriented evaluation that follows the principle
of ‘‘information synthesis” used in recent document understanding
conference evaluations. As a surrogate for a physician-annotated
reference standard, we semiautomatically compiled drug therapies
for 53 topics from the June 2004 issue of Clinical Evidence concise,
published by the British Medical Journal. This resource was en-
hanced with topic-drug information from the Physicians’ Desk Ref-
erence. PubMed searches were issued for the 53 disorders studied,
and the MEDLINE citations retrieved were processed by the sum-
marization system. A baseline was also created by identifying the
ﬁve most frequently occurring drugs in the citations retrieved for
each disorder. Results from the summarization system and the
baseline method were automatically compared to the reference
standard, and two performance metrics were calculated: mean
average precision and a clinical usefulness score, which penalized
results that included drugs known to be harmful. The quality of
automatic evaluation was checked through a manual assessment
of the summarization results for four diseases. The summarization
system scored signiﬁcantly higher than the baseline on both
metrics.
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Interventions as Metathesaurus concepts found by the summarization system for each topic included in the study. In the last column, the
ﬁrst number inside the parenthesis is frequency of occurrence and the second number is typicality.Disease class Topic InterventionsBlood and lymph
disordersEarly stage aggressive non-
Hodgkin’s lymphomaNONECardiovascular
disordersAcute ischemic stroke Alteplase(8/6); Aspirin(5/3); Ancrod(4/2)Acute myocardial infarction Thrombolytic Therapy(52/37); Alteplase(28/20); Streptokinase(22/19);
Angiotensin-Converting Enzyme Inhibitors(17/13); Reperfusion Therapy(16/13);
Fibrinolytic Agents(15/15); Aspirin(11/9); Angioplasty, Transluminal, Percutaneous
Coronary(9/6); Heparin(8/7); Captopril(8/6); Angioplasty(7/6); reteplase(7/6);
Administration (procedure)(6/6); Metoprolol(5/4); Thrombin(4/4); Unfractionated
heparin (substance)(4/2); Ramipril(4/3); Lisinopril(4/2); Heparin, Low-Molecular-
Weight(3/2)Atrial ﬁbrillation Digoxin(13/7); Diltiazem(8/4); Anticoagulant therapy (procedure)(5/2);
Verapamil(2/2); esmolol(2/2); Amiodarone(2/1)Heart failure carvedilol(19/12); Adrenergic beta-Antagonists(16/12); Angiotensin-Converting
Enzyme Inhibitors(11/10); Metoprolol(10/8); Digoxin(8/5); valsartan(6/4)Unstable angina Heparin(27/21); Aspirin(13/12); Unfractionated heparin (substance)(12/9);
Propranolol(11/5); Metoprolol(11/5); Alteplase(9/5); Enoxaparin(7/5);
Nifedipine(6/4); Heparin, Low-Molecular-Weight(5/5); tiroﬁban(5/5);
Calcium Channel Blockers(3/2); inogatran(3/2); Thrombin(2/2);
GENERAL OPERATIVE PROCEDURES(2/2); Hirudin(2/2); Coronary
Artery Bypass(2/2)(continued on next page)
810 M. Fiszman et al. / Journal of Biomedical Informatics 42 (2009) 801–813Appendix A (continued)Disease class Topic InterventionsChild health Acute otitis media Amoxicillin(51/34); Cefaclor(39/24); Clavulanate(25/13); Antibiotics(22/19);
Amoxicillin-Potassium Clavulanate Combination(16/12); Ceftriaxone(16/7)Digestive system
disordersGastroesophageal reﬂux
diseaseOmeprazole(42/29); Cisapride(33/23); Ranitidine(29/21); Metoclopramide(22/15);
Cimetidine(14/10); lansoprazole(10/8); Proton pump inhibitor (substance)(8/8);
pantoprazole(6/5); Baclofen(5/3); rabeprazole(5/3); Antacids(4/3); Famotidine
(3/2); Domperidone(3/1)Irritable bowel syndrome Excluded from study. Search did not ﬁnd citations.
Ear, nose, and
throat disorders
Acute sinusitis Amoxicillin(8/5); Doxycycline(7/4); cefuroxime axetil(6/4)Otitis externa Otosporin(3/2); Tobrex(2/1)
Seasonal allergic rhinitis Loratadine(20/13); Cetirizine(20/13); Budesonide(17/13); Antihistamines(14/14);
Terfenadine(13/9); Adrenal Cortex Hormones(12/8); Beclomethasone
Dipropionate(11/8); Fluticasone propionate(11/10); ebastine(10/6); Cromolyn
Sodium(8/4); Triamcinolone Acetonide(8/6); acrivastine(7/3); Fexofenadine
hydrochloride(7/3); fexofenadine(7/6); levocabastine(6/3); Azelastine(6/5);
Pseudoephedrine(5/4); Astemizole(4/4); The science and art of healing(3/3);
Beclomethasone(3/3)Endocrine
disordersHypothyroidism Thyroxine(11/9); Replantation(2/2); Triiodothyronine(2/2); Thyroxine therapy
(2/2)Obesity sibutramine(25/15); orlistat(24/22); Fluoxetine(20/14); Dexfenﬂuramine(14/11);
Metformin(12/11); Leptin(7/3); Insulin(7/7); troglitazone(5/4); Gemﬁbrozil(4/2);
Dietary Supplementation(3/3); Calorie restricted diet (ﬁnding)(3/3)Eye disorders Bacterial conjunctivitis Eyedrops(2/2); Ciproﬂoxacin(2/2); Oﬂoxacin(2/1)
Glaucoma Timolol(13/9); Adrenergic beta-Antagonists(13/8); brimonidine(7/5);
Epinephrine(5/5); Pilocarpine(4/4); Trabeculectomy(4/4); Eyedrops(4/4);
Mitomycin(4/4); 4-benzamido-4’-isothiocyanostilbene-2,2’-disulfonate(3/2);
Betaxolol(3/3)HIV and AIDS Pneumocystis carinii
pneumoniaTrimethoprim-Sulfamethoxazole Combination(24/20); Pentamidine(11/9);
Prophylactic treatment(10/8); Adrenal Cortex Hormones(7/6); Dapsone(4/2);
hydroxynaphthoquinone 566C80(3/2)Infectious diseases Acute diarrhea Octreotide(17/10); Loperamide(7/4); Octreotide Acetate(6/4); nitazoxanide(4/3);
Fluorouracil(4/3); Chemotherapy-Oncologic Procedure(3/2); alosetron(3/2);
Radiation therapy(2/2); Antibiotics(2/2); Roxithromycin(2/1); Antidiarrheals(2/1);
Administration, Oral(2/1); Thalidomide(2/2); Smectite(2/1); Albendazole(2/1);
Metronidazole(2/2)Bacterial meningitis Ceftriaxone(19/12); Chloramphenicol(8/7); Cefotaxime(7/6); Ampicillin(5/5)
Chickenpox Acyclovir(18/13)
Congenital toxoplasmosis NONE
Malaria Chloroquine(5/5); Meﬂoquine(4/3); halofantrine(3/1); sulfadoxine-
pyrimethamine(3/2)
Men’s health Chronic prostatitis Ciproﬂoxacin(6/5)Erectile dysfunction sildenaﬁl(96/55); Alprostadil(57/36); Viagra(29/24); Sildenaﬁl citrate(28/21);
Apomorphine(9/5); Phentolamine(7/4); Injections(6/6); Intracavernous injection
(procedure)(6/6); Papaverine(5/4); Glonoine, nitroglycerine, Homeopathic
preparation(4/2)Mental health Dementia Risperidone(5/4); olanzapine(4/3); Antipsychotic Agents(4/2); donepezil(4/3);
Ginkgo biloba extract(4/2); Melatonin(2/1); The science and art of healing(2/2);
Levodopa(2/2)Depressive disorder Fluoxetine(23/18); Antidepressive Agents(17/17); Paroxetine(10/9); Serotonin
Uptake Inhibitors(10/9); Imipramine(9/5); Release procedure(7/6); nefazodone(7/
4); reboxetine(6/2); Sertraline(6/4); Fluvoxamine(6/4); Nortriptyline(5/4);
venlafaxine(5/4); Amitriptyline(4/3); Psychotherapy(4/3); Tryptophan(3/3);
Mirtazapine(3/2); Augmentation procedure (procedure)(3/3); Desipramine(2/2);
Testosterone(2/1); olanzapine(2/2); Citalopram(2/2); Interventions(2/2);
Pharmacotherapy(2/2); Bupropion(2/2); Electroconvulsive Therapy(2/2);
Administration (procedure)(2/1)Generalized anxiety disorder NONE
Mania Lithium(16/13); Verapamil(8/6); Valproate(6/5); Carbamazepine(6/6); Haldol
decanoate, homeopathic preparation(6/6); Antipsychotic Agents(5/5);
olanzapine(4/4); The science and art of healing(4/4); Clozapine(4/2); Antimanic
Agents(4/4); Electroconvulsive Therapy(3/2); Risperidone(3/3)
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Benzodiazepines(15/8); Sertraline(14/8); Alprazolam(14/12); Serotonin Uptake
Inhibitors(12/12); Clomipramine(12/11); Cognitive Therapy(10/7); Fluvoxamine(9/
6); Antidepressive Agents(8/6); Behavior Therapy, Cognitive(8/4); venlafaxine(7/
3); Interventions(4/2)Post-traumatic stress
disorderSertraline(15/7); Fluoxetine(12/8); nefazodone(11/5); Mirtazapine(6/3);
Paroxetine(5/3)Schizophrenia Antipsychotic Agents(41/32); Clozapine(37/28); Haldol decanoate, homeopathic
preparation(35/28); olanzapine(30/24); Risperidone(29/23); Atypical antipsychotic
(substance)(8/8); The science and art of healing(3/3)Musculoskeletal
disordersAcute low back pain tenoxicam(4/1)Leg cramps NONE
Osteoarthritis Naproxen(45/35); Anti-Inﬂammatory Agents, Non-Steroidal(34/27); Piroxicam(33/
27); Diclofenac(31/24); nabumetone(24/18); Indomethacin(19/15); Ibuprofen(17/
13); Etodolac(12/10); Anti-Inﬂammatory Agents(8/7); Aspirin(7/4); meloxicam(7/
5); Hyaluronic Acid(6/5); tenoxicam(5/5); Acetaminophen(5/4); Cyclooxygenase-2
Inhibitors(4/3); Misoprostol(4/4); Sulindac(4/3)Osteoporosis Alendronate(12/9); Etidronate(9/7); Natrium ﬂuoratum, sodium ﬂuoride,
Homeopathic preparation(7/6); amidronate(7/4); Fluorides(6/4); Raloxifene(5/2);
Vitamin D(4/2); Calcitriol(3/3); Parathyroid Hormones(2/2); Calcitonin(2/2);
salmon calcitonin(2/2); Methandrostenolone(2/2); Calcium supplementation(2/2);
Estrogens(2/2)Rheumatoid arthritis Methotrexate(108/72); Cyclosporine(27/18); Sulfasalazine(21/16);
leﬂunomide(20/14); Disease-Modifying Second-Line Drugs(17/11); The science
and art of healing(16/15); Combination electrotherapy(15/12); interleukin-1
receptor antagonist(11/5); Minocycline(11/6); Diclofenac(9/8); meloxicam(8/5);
Auranoﬁn(8/7); Adrenal Cortex Hormones(7/7); Cyclophosphamide(7/5); Anti-
Inﬂammatory Agents, Non-Steroidal(6/6); Administration (procedure)(6/5);
Glucocorticoids(5/4); Antirheumatic Agents(5/5); Anti-Inﬂammatory Agents(5/5);
Hydroxychloroquine(5/4); aceclofenac(5/3); Erythropoietin, Recombinant(4/2)Neurological
disordersEpilepsy Vigabatrin(29/22); Carbamazepine(24/20); Antiepileptic Agents(23/19);
lamotrigine(21/17); Phenytoin(14/10); Valproate(13/9); Valproic Acid(10/8);
clobazam(6/3); Phenobarbital(5/5); topiramate(5/5); felbamate(5/3);
gabapentin(5/4); tiagabine(4/3); Flunarizine(3/3); Anticonvulsants(3/3)Migraine Sumatriptan(129/87); Metoclopramide(17/13); rizatriptan(14/9); zolmitriptan(13/
7); almotriptan(12/8); Dihydroergotamine(10/8); frovatriptan(9/4); 311C90(9/5);
Acetaminophen(9/7); Prochlorperazine(8/4); naratriptan(7/5); Flunarizine(7/6);
eletriptan(7/6); Valproate(6/2); Caffeine(6/4); Analgesics(5/5); Ibuprofen(5/3);
Propranolol(4/4); Sodium Valproate(4/4); Administration (procedure)(4/4);
avitriptan(4/2); Anti-Inﬂammatory Agents, Non-Steroidal(3/3); Meperidine(3/2)Multiple sclerosis Methylprednisolone(23/18); Azathioprine(13/8); interferon beta 1a(11/7);
Interferon-beta(9/6); interferon beta-1b(7/5); Corticotropin(6/4); Therapeutic
immunosuppression(6/6); gabapentin(6/5); Cyclosporine(5/5); Baclofen(5/5);
Amantadine(5/3); Interferon-alpha(5/4); Cyclophosphamide(4/3); tizanidine(4/2);
Copaxone(4/4); Isoniazid(4/3); The science and art of healing(4/4); Avonex(4/4)Parkinson disease Levodopa(79/62); Bromocriptine(20/16); Dopamine Agonists(19/15);
Apomorphine(17/13); pramipexol(16/11); ropinirole(15/12); Selegiline(15/10);
tolcapone(9/8); Deprenil(9/5); Pergolide(8/6); Stimulation - action (qualiﬁer
value)(8/7); entacapone(8/6); cabergoline(8/6); budipine(8/3); Carbidopa(6/5);
Amantadine(5/3); olanzapine(4/4); Anticholinergic Agents(3/2)Trigeminal neuralgia Baclofen(7/4); Carbamazepine(3/3); Capsaicin(2/2); Anticonvulsants(2/1)
Oral health Oropharyngeal candidiasis Clotrimazole(10/8); Miconazole(8/4); Fluconazole(8/5); Nystatin(7/5)
Respiratory
disorders
(acute)Acute asthma Albuterol(44/31); Adrenal Cortex Hormones(12/12); Epinephrine(11/9)Acute bronchitis Erythromycin(10/7); Amoxicillin(7/4); Antibiotics(6/4); Cefaclor(6/4); cefuroxime
axetil(4/3); Azithromycin(4/2); dirithromycin(3/2); Clavulanate(3/2); Amoxicillin-
Potassium Clavulanate Combination(2/1)Community acquired
pneumoniaAzithromycin(10/4); Clarithromycin(7/4); ANTIMICROBIALS(4/4); Erythromycin(4/
3); Ceftriaxone(4/3); Antibiotics(3/2); Amoxicillin(3/2); Oﬂoxacin(3/2);
Cefonicid(2/1)(continued on next page)
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disorders
(chronic)Chronic asthma Albuterol(34/31); Adrenal Cortex Hormones(32/29); Theophylline(28/22);
Beclomethasone Dipropionate(22/16); Bronchodilator Agents(19/17);
Budesonide(17/12); Leukotriene Antagonists(15/10); montelukast(12/12);
salmeterol(9/7); Beclomethasone(9/8); Cyclosporine(8/5); Fenoterol(8/7);
Fluticasone propionate(7/7); Nedocromil, Disodium Salt(7/5); Ipratropium
Bromide(6/6); ﬂunisolide(5/3); Terbutaline(5/5); Anti-Inﬂammatory Agents(3/3);
The science and art of healing(3/3)Chronic obstructive
pulmonary diseasesalmeterol(10/8); Adrenal Cortex Hormones(7/6); Bronchodilator Agents(7/5);
Ipratropium Bromide(6/4); Fluticasone propionate(6/5); Theophylline(6/4);
formoterol(6/3); tiotropium(5/3); Almitrine Bismesylate(3/1)Sexual health Chlamydia infection Doxycycline(9/7); Oﬂoxacin(8/6); Azithromycin(6/5); Erythromycin(5/5)
Genital warts Podophyllotoxin(20/12); imiquimod(8/4); Isotretinoin(7/3); Emollient Cream(6/5);
Fluorouracil(6/3); Podophyllin(4/3)
Gonorrhea Ceftriaxone(41/30); Probenecid(25/20); Ciproﬂoxacin(19/12); Oﬂoxacin(17/11);
Penicillin(13/12); Spectinomycin(13/13); cefuroxime axetil(11/6); Cefotaxime(11/
7); Amoxicillin(9/7); Ceﬁxime(9/7); Trimethoprim-Sulfamethoxazole
Combination(7/5); Aztreonam(7/4); Azithromycin(7/4); Enoxacin(7/5); Penicillin
G, Procaine(6/6); Quinolones(5/5); Augmentin(5/3); Thiamphenicol(4/3);
Ampicillin(4/4); Antibiotics(3/3); Penicillin G(3/3)Skin disorders Atopic eczema Cyclosporine(41/21); Tacrolimus(23/13); Emollient Cream(22/19); The science and
art of healing(7/5); gamma-Linolenic Acid(4/3); Antihistamines(3/2);
Betamethasone valerate(3/3);Chronic psoriasis Cyclosporine(17/13); calcipotriene(6/5); Anthralin(5/5); Tacalcitol(4/3); PUVA(4/
4); alefacept(3/2); Retinoids(3/3);Scabies Ivermectin(19/9);
Tinea pedis Emollient Cream(24/15); terbinaﬁne(15/10); Griseofulvin(7/4); Itraconazole(7/4);References
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